# The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients

> **NCT04195919** · PHASE1 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Hemodialysis Patients

## Interventions

- **DRUG:** Evogliptin 5mg
- **DRUG:** Evogliptin 5mg

## Key facts

- **NCT ID:** NCT04195919
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-10
- **Primary completion:** 2021-05-24
- **Final completion:** 2021-05-24
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04195919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04195919, "The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04195919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*